KRAS degradation averts PDAC chemoresistance

被引：0
|
作者：
Leonhardt, Laura [1 ,2 ,3 ]
Hebrok, Matthias [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Tech Univ Munich, TUM Sch Med & Hlth, Munich, Germany
[2] Tech Univ Munich, Ctr Organoid Syst, Garching, Germany
[3] Inst Diabet & Organoid Technol, Helmholtz Diabet Ctr, Helmholtz Zentrum Munchen, Neuherberg, Germany
[4] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Munich, Germany
[5] German Ctr Diabet Res DZD, Neuherberg, Germany
[6] Univ Calif San Francisco, Diabet Ctr, Dept Med, San Francisco, CA 94143 USA
来源：
NATURE CANCER | 2024年 / 5卷 / 03期
关键词：
D O I：
10.1038/s43018-023-00708-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
引用
收藏
页码：375 / 377
页数：3
相关论文
共 50 条
  • [31] Inflammation mediated expression of integrin αvß3 potentiates KRAS driven PDAC oncogenesis
    Shepard, Ryan M.
    Campos, Alejandro D.
    Ortega, Zachary M.
    Wettersten, Hiromi I.
    Von Schalscha, Tami
    Weis, Sara M.
    Cheresh, David A.
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Targeting KRAS G12D/V mutations by KR12 in PDAC
    Matsuo, Nina
    Inoue, Takahiro
    Yoda, Hiroyuki
    Takatori, Atsushi
    Shinozaki, Yoshinao
    Watanabe, Takayoshi
    Koshikawa, Nobuko
    Jason, Lin
    Nagase, Hiroki
    CANCER SCIENCE, 2018, 109 : 518 - 518
  • [33] Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors
    Anastasio, Giorgia
    Felaco, Michela
    Lamolinara, Alessia
    del Pizzo, Francesco
    Cacciagrano, Elisa
    Mottini, Carla
    Mutarelli, Margherita
    Di Modugno, Francesca
    Iezzi, Manuela
    Cardone, Luca
    ISCIENCE, 2025, 28 (02)
  • [34] Quantitative flux measurements of serum protein catabolism in PDAC and other KRAS-mutant cancers
    Nofal, Michel
    Zhang, Kevin
    Rabinowitz, Josh
    CANCER RESEARCH, 2015, 75
  • [35] RARS2 Promotes Invasion and Chemoresistance of PDAC by P53-Dependent Apoptosis Signaling
    Yueze, Liu
    Zhang, Taiping
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S301 - S301
  • [36] Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
    Liu, Yonghong
    Han, Jincheng
    Hsu, Wen-Hao
    Labella, Kyle A.
    Deng, Pingna
    Shang, Xiaoying
    de Lara, Paulino Tallon
    Cai, Li
    Jiang, Shan
    Depinho, Ronald A.
    CANCER DISCOVERY, 2025, 15 (01) : 162 - 178
  • [37] Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).
    George, Ben
    Greenbowe, Joel R.
    Hendifar, Andrew Eugene
    Golan, Talia
    Javle, Milind M.
    Maitra, Anirban
    Bahary, Nathan
    Schrock, Alexa Betzig
    Stephens, Philip J.
    Miller, Vincent A.
    Ross, Jeffrey S.
    Yakirevich, Evgeny
    Ritch, Paul S.
    Thomas, James P.
    Ali, Siraj Mahamed
    Singhi, Aatur D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Inhibition of Telomerase Activity Suppresses Kras Mutation-Induced Lung Carcinogenesis and Chemoresistance
    Zhang, Bin
    Yin, Yuesong
    Zhang, Hua
    Shi, Bowen
    Zhu, Jinfang
    Wang, Changli
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S453 - S453
  • [39] Tanshinone I attenuates proliferation and chemoresistance of cervical cancer in a KRAS-dependent manner
    Dun, Sidi
    Gao, Lan
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2019, 33 (04)
  • [40] Characterization of next generation (Gen2.5) KRAS antisense inhibitors in NSCLC, PDAC, and CRC models
    Revenko, Alexey S.
    Bhattachrjee, Gourab
    May, Chris
    Monia, Brett P.
    MacLeod, A. Robert
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345